Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a ...

Sanofi (Euronext: SAN) has announced that the UK's health technology assessor will conduct a new review of its Sarclisa ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...

Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Sanofi will keep a significant stake in the ... Another great milestone is the approval with Sarclisa in the US for adult patients with newly diagnosed multiple myeloma ineligible for transplantation.

Sanofi SNY reported third-quarter 2024 adjusted ... over year to €92 million due to generic competition. In Oncology, Sarclisa sales rose 23.7% year over year to €114 million, driven by ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

were reported The results of Sanofi’s phase 3 IMROZ trial have allowed for the expanded indication of Sarclisa. Previously approved only for patients with previously treated multiple myeloma (MM), the ...

Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

It also vowed to keep Opella's headquarters in France, the same source added. Read also: USFDA nod to Sanofi Sarclisa in combo with bortezomib, lenalidomide, dexamethasone for newly diagnosed multiple ...